益赛普联合甲氨蝶呤治疗活动性类风湿关节炎的临床观察  

Treatment of etanercept and methotrexat on active rheumatoid arthritis

作　　者：许百洁[1] 李奕琏[1] 

机构地区：[1]揭阳市人民医院,广东揭阳522000

出　　处：《西部医学》2010年第12期2255-2256,共2页Medical Journal of West China

摘　　要：目的观察益赛普联合甲氨蝶呤(MTX)治疗活动性类风湿关节炎的疗效及安全性。方法 47例患者随机分为两组,试验组(24例),甲氨蝶呤每周定量口服10～15 mg 1次,联合益赛普50 mg,每周皮下注射1次;对照组(23例),甲氨蝶呤每周定量口服10～15 mg 1次,疗程12周。以ACR20为主要评估指标,ACR50及各具体观察指标为次要评估指标。结果试验组ACR20及各具体观察指标与对照组间比较差异有统计学意义(P<0.05)。ACR50试验组比例高于对照组,但组间差异无统计学意义(P>0.05)。试验期间,未出现严重不良反应。结论益赛普联合甲氨蝶呤治疗活动性类风湿关节炎安全,有效。Objective To observe and evaluate the effect and safety of the etanercept and methotrexat on treatment of active rheumatoid arthritis.Methods 42 patients were divided into two groups randomly including Control group treated with methotrexat（MTX） and etanercept and Trial group treated with methotrexat（MTX）.Results ACR50 of the control group was higher than that of the trial group,while the difference between these two groups had no statistical significance（P0.05）.During the trial,no serious side-effect occurred.Conclusion The etanercept treatment for activated rheumatoid arthritis is more safe and effective.

关 键 词：益赛普 甲氨蝶呤 类风湿关节炎 

分 类 号：R593.22[医药卫生—内科学]